Shuttle Pharmaceuticals Enters Material Agreement, Reports Equity Sales
Ticker: SHPH · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.3 million, $600,000, $231,579, $220,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Shuttle Pharma inked a deal & sold stock, filing shows.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announced on October 21, 2024, the entry into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this summary.
Why It Matters
This filing indicates a significant business development for Shuttle Pharmaceuticals, potentially impacting its financial standing and future operations through a new agreement and equity transactions.
Risk Assessment
Risk Level: medium — The filing involves a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41488 (identifier) — SEC File Number
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Shuttle Pharmaceuticals Holdings, Inc. on October 21, 2024?
The filing states that Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on October 21, 2024, but the specific details of this agreement are not disclosed in the provided text.
What were the details of the unregistered sales of equity securities reported by Shuttle Pharmaceuticals Holdings, Inc.?
The filing indicates that Shuttle Pharmaceuticals Holdings, Inc. reported unregistered sales of equity securities, but the specific terms, amounts, and recipients of these sales are not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item of information, but the specific content of these statements and exhibits is not detailed in the provided text.
When was the earliest event reported in this Form 8-K filing?
The earliest event reported in this Form 8-K filing occurred on October 21, 2024.
What is the principal executive office address for Shuttle Pharmaceuticals Holdings, Inc.?
The principal executive office address for Shuttle Pharmaceuticals Holdings, Inc. is 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 793 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-10-25 08:52:30
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $1.3 million — ion (the "Company"), commenced an up to $1.3 million offering (the "Offering") of 5% origina
- $600,000 — nts ("Warrants"), closing on an initial $600,000 in investments on October 14, 2024 (the
- $231,579 — 24, the Company closed on an additional $231,579 in Notes and Warrants purchased in the
- $220,000 — cond Closing"), receiving an additional $220,000 in proceeds and bringing the Offering t
- $790,000 — g to a close after receiving a total of $790,000 in gross proceeds, including $237,500 i
- $237,500 — f $790,000 in gross proceeds, including $237,500 invested by the Company's Chief Executi
- $1.49 — tes and 88,544 Warrants, exercisable at $1.49 per share, or 125% of the closing price
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-042462.txt ( ) — 217KB
- shph-20241021.xsd (EX-101.SCH) — 3KB
- shph-20241021_lab.xml (EX-101.LAB) — 33KB
- shph-20241021_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: October 25, 2024 By: /s/ Timothy Lorber Name: Timothy Lorber Title: Chief Financial Officer